
Despite an embrace of greater patient populations by the FDA, cardiovascular research into stem cell therapy has been slow and burdened.
Despite an embrace of greater patient populations by the FDA, cardiovascular research into stem cell therapy has been slow and burdened.
As safety and efficacy programs advance, clinicians consider the investigative therapy's potential in cardiology.
Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.
It wasn't long ago that researchers first identified a piece of DNA that regulates cholesterol. This gene has been recently developed into a cholesterol-lowering agent and it's time to address where we go from here.